Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01243541 · ClinicalTrials.gov registry record · NA
Cryotherapy in Preventing Peripheral Neuropathy and Nail Toxicity in Patients With Breast Cancer Who Are Receiving Paclitaxel
A NA study, sponsored by Northwestern University.
- Terminated
- Registry status
- NA
- Development phase
- 33
- Enrollment target
NCT01243541 is a NA study that was terminated before completion, run by Northwestern University. The registered enrollment target is 33 participants.
The verdict
NCT01243541, a NA study, was terminated before completion, sponsored by Northwestern University.
- TERMINATED
- Registry status
- NA
- Development phase
- 33 participants
- Enrollment target
Study Summary
RATIONALE: Cryotherapy may help prevent peripheral neuropathy or nail toxicity in patients receiving chemotherapy. PURPOSE: This clinical trial studies cryotherapy in preventing peripheral neuropathy and nail toxicity in patients with breast cancer who are receiving paclitaxel.
Interventions
- OTHER questionnaire administration
- PROCEDURE quality-of-life assessment
- PROCEDURE management of therapy complications
- PROCEDURE assessment of therapy complications
- PROCEDURE cryotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2010-11-03 |
| Est. Completion | 2014-04-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01243541
The ClinicalTrials.gov registry entry for NCT01243541 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which questionnaire administration is the first listed.
NCT01243541 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01243541 about?
NCT01243541 is a clinical study titled "Cryotherapy in Preventing Peripheral Neuropathy and Nail Toxicity in Patients With Breast Cancer Who Are Receiving Paclitaxel". RATIONALE: Cryotherapy may help prevent peripheral neuropathy or nail toxicity in patients receiving chemotherapy. PURPOSE: This clinical trial studies cryotherapy in preventing peripheral neuropathy and nail toxicity in patients with breast cancer who are receiving paclitaxel.
What is the current status of trial NCT01243541?
This trial is currently terminated. It is a NA study. The enrollment target is 33 participants. The study started on 2010-11-03. Estimated completion is 2014-04-04.
What interventions are being tested in trial NCT01243541?
The interventions under investigation include: questionnaire administration (OTHER), quality-of-life assessment (PROCEDURE), management of therapy complications (PROCEDURE), assessment of therapy complications (PROCEDURE), cryotherapy (PROCEDURE).
Who is sponsoring clinical trial NCT01243541?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.